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ABSTRACTS 1259receptor activation. We found high levels of nitric oxide
associated with Fas receptor resistance in nasal polyp
tissues. Therefore, inhibition of apoptosis of eosinophils
can be achieved by increased expression of survival factors
and disruption of death signals. Future studies will show
whether additional mechanisms exist.
The intracellular regulation of apoptosis includes mem-
bers of the Bcl-2 family. Normal eosinophils express
significant levels of Bcl-xL and Bax, but no or little Bcl-
xS and Bcl-2 (11). In allergic diseases, IL-5 upregulates Bcl-
xL, but does not alter Bax, Bcl-xS or Bcl-2 levels in
eosinophils. In contrast, Bcl-2 is expressed in eosinophils
derived from a subgroup of patients with the hypereosino-
philic syndrome (12). Overexpression of Bcl-2 in eosino-
phils delays eosinophil apoptosis in a cytokine-independent
manner.
In conclusion, delayed eosinophil apoptosis is an
important pathogenic event, which contributes to
eosinophil accumulation in diseases associated with eosi-
nophilia. Several mechanisms are described that may
participate in the inhibition of the death process. The
identification of molecules involved in the anti-apoptosis
pathways in eosinophils offers hope for the development of
new drugs that reduce inflammation in eosinophilic
disorders.
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burgh, EH8 9AG, U.K.Eosinophilic granulocytes play a key role in the host’s
defence against invading organisms; for example, they play
a particularly prominent role in the fight against parasitic
infection. They are also involved in orchestrating the
pathogenesis and propagation of certain allergic and
inflammatory diseases such as allergic rhinitis and asthma
(1). It has become abundantly clear that the development of
chronic inflammatory diseases depend not only upon the
recruitment and activation of inflammatory cells but also
upon their subsequent removal from the inflammatory
milieu (2). Apoptosis or programmed cell death is now
regarded as a fundamental process regulating inflammatory
cell survival and is critically involved in ensuring the
successful resolution of an inflammatory response (2). This
process therefore provides an ecient non-inflammatory
mechanism for removal of potentially highly histotoxic cells
from the inflamed site after the useful function of these cells
has been served. Therefore, together with preventing
excessive granulocyte invasion and activation, a parallel
strategy of selectively inducing apoptosis and augmenting
phagocytic removal of these cells should prove beneficial
for the development of novel therapeutic targets (2,3).
Eosinophils and neutrophils have a similar ontogeny, in
that they are derived from a common myeloid precursor,
and when activated these cells can exhibit similar functional
Fig. 1. The effect of cycloheximide on constitutive
eosinophil apoptosis. Eosinophils (26106/ml), cultured in
Iscoves DMEM supplemented with 10% autologous
serum, were untreated (open bar) or treated with 50mM
cycloheximide (filled bar) and apoptosis assessed
morphologically after 20 h of culture (a minimum of 500
cells were examined per slide). Each treatment was
performed in triplicate and the data represent the
mean+SEM of 4 separate experiments. *P50?05
compared with control.
1260 ABSTRACTSresponses. Comparison of functional responses in these cell
types has proven to be a useful tool to understand
granulocyte behaviour, including apoptosis. Several prim-
ing and pro-inflammatory cytokines present at an inflam-
matory site not only affect granulocyte responsiveness but
can also delay the natural constitutive rate of apoptosis.
For example, IL-5 and GM-CSF cause a very profound
inhibition of eosinophil apoptosis in vitro and a similar
effect is observed in neutrophils exposed to LPS or GM-
CSF (2,3). Thus selective promotion of apoptosis by
blocking the influence of these survival factors may be
achievable. In addition, it has been convincingly demon-
strated that the constitutive rate of neutrophil and
eosinophil apoptosis can be regulated in a selective manner;
glucocorticoids and agents that elevate cytosolic Ca2+
induce eosinophil apoptosis whereas such agents delay
neutrophil apoptosis (2,4–6). Furthermore, the recent
observation that glucocorticoids dramatically up-regulate
the capacity of macrophages to phagocytose apoptotic
cells, including eosinophils and neutrophils, by a non-
inflammatory mechanism has underpinned the importance
of studying and targeting this natural cell suicide process
(7). In support of these in vitro observations, it has recently
been demonstrated that amelioration of the clinical
symptoms of asthma by treating asthmatic patients with
oral corticosteroids causes a major increase in the number
of phagocytosed apoptotic eosinophils appearing in the
sputum. This strongly indicates the importance of these
processes in clinical situations (8). Therefore, understand-
ing the molecular mechanisms controlling granulocyte
apoptosis in general and unravelling the reasons why
eosinophil and neutrophil apoptosis is regulated differently
may help in the search for novel therapeutic targets. It has
become apparent that both granulocytes, despite being
terminally differentiated, are transcriptionally active and
consequently have the capacity to synthesize specific
proteins. Neutrophils, for example, can synthesize and
release a number of inflammatory mediators (e.g. IL-8,
GM-CSF) which can themselves influence cell responsive-
ness and regulate apoptosis (9). Similarly, eosinophils are
capable of synthesizing a plethora of inflammatory
cytokines and chemokines (1). Recently, we have shown
that eosinophils, in response to pharmacological stimuli
(e.g. PMA) and physiological secretagogues (e.g. IL-5,
C5a), release the pro-inflammatory cytokine macrophage
migration inhibitory factor (MIF). PMA-induced MIF
secretion is attenuated by cycloheximide and a protein
kinase C inhibitor Ro 31-8220 indicating that protein
synthesis and protein kinase C activation are involved in
MIF secretion (10). Interestingly, BAL fluid obtained from
asthmatic patients contained significantly higher levels of
MIF than BAL fluid obtained from normal subjects (10).
Despite the fact that granulocytes clearly have the capacity
to synthesize and secrete proteins and that investigations
into transcriptional regulation of granulocyte responsive-
ness and apoptosis is in its infancy, some transcription
factors have been identified as playing a significant
regulatory role. Many of the transcription factors identified
so far have yet to be directly demonstrated in granulocytes
and shown to be involved in their subsequent behaviour.These transcription factors are proteins usually located in
the cytoplasm that translocate to the nucleus when
activated. They then bind to regulatory sequences, usually
in the upstream (5’) promoter region of target genes that
control the rate of gene transcription. This results in altered
protein synthesis of important cytokines, receptors, adhe-
sion molecules, etc, which orchestrate the inflammatory
response.
The constitutive rate of neutrophil apoptosis can be
enhanced by blockade of protein synthesis using agents
such as actinomycin D and cycloheximide suggesting that
synthesis of proteins limit induction of apoptosis in
neutrophils (11). This is somewhat different in other cell
systems, for example, thymocyte apoptosis is suppressed by
protein synthesis inhibition. There is also evidence that
eosinophil apoptosis, like the neutrophil, can be enhanced
by inhibition of protein synthesis (12, Fig. 1). In addition,
IL-5 and GM-CSF mediated survival of human eosinophils
(13) and neutrophils (14) respectively are prevented by
protein synthesis inhibition. Recent evidence indicates that
the eosinophil survival agents IL-5, IL-3 and GM-CSF
share common signal transducers and mediate their
responses via the Lyn–Ras–Raf-1-MAP kinase pathway
and the pathways involving the Janus kinase (JAK)/signal
transduction and activation of transcription (STAT) family
(see 1, 15, 16 for reviews).
We have recently shown that the ubiquitous transcription
factor NF-kB plays a critical role in controlling apoptosis
both in neutrophils and eosinophils (17). Due to the
relatively short life of both cells in vitro and the consequent
diculty of performing long-term molecular biological
techniques on these cells, we have relied heavily on a
pharmacological approach to investigate the role of
transcription factors in regulating granulocyte apoptosis.
For this, we have used specific inhibitors of NF-kB to probe
the role of this transcription factor. We have shown that the
Fig. 2. Possible role of NF-kB in eosinophil apoptosis
Activation of cell surface receptors by cognate ligands
may result in NF-kB activation resulting in the
production of survival proteins which inhibit apoptosis.
Blockade of the NF-kB pathway by specific agents such as
gliotoxin may lead to the inhibition of survival by the
induction of apoptosis.
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similar inactive analogue, methylthiogliotoxin, greatly
accelerated the onset of apoptosis of both neutrophils and
eosinophils (17). The induction of neutrophil apoptosis was
mimicked by other agents that interfere with the NF-kB
pathway (e.g. curcumin, PDTC, MG-132 and the cell
permeable inhibitory peptide SN50). In neutrophils, the
pro-survival bacterial product LPS, and the cytokine TNF-
a which induces an early pro-apoptotic effect followed by a
later anti-apoptotic effect (18), directly stimulated NF-kB
translocation from the cytoplasm to the nucleus as assessed
by electrophoretic mobility shift assays. Gliotoxin selec-
tively inhibited the NF-kB activation process and enhanced
dramatically the pro-apoptotic effect of TNF-a.
In addition, cycloheximide similarly enhanced TNF-a
induced neutrophil apoptosis even at time points when
cycloheximide alone exerted no pro-apoptotic effect. Taken
together these data indicate that NF-kB may regulate the
production of protein(s) which protects neutrophils from
the cytotoxic effect of TNF-a. In the eosinophil, TNF-a
alone failed to alter the rate of constitutive apoptosis,
however, when these cells were cultured simultaneously
with TNF-a and gliotoxin there was a dramatic synergistic
enhancement of apoptosis indicating that blockade of NF-
kB could unmask the ability of TNF-a to induce apoptosis
in eosinophils (17). Although we have detected the presence
of the inhibitory subunit of NF-kB, kIkBa, in eosinophils
(Fujihara, Ward and Rossi, unpublished observations) the
precise mechanism of NF-kB inhibition by gliotoxin and
other inhibitors in granulocytes is still to be determined (see
Fig. 2). Despite this, it is abundantly clear that the
transcription factor NF-kB plays a crucial role in regulating
apoptosis in both neutrophils and eosinophils.
Glucocorticoids exert differential effects on granulocyte
behaviour e.g. dexamethasone induces eosinophil apoptosis
whereas neutrophil apoptosis it delayed. It is therefore of
great scientific and clinical interest to understand the
mechanisms controlling these differences particularly in
view of the wide use in managing inflammatory diseases.
Despite the fact that the effects of glucocorticoids on
granulocyte apoptosis are mediated by ligation of gluco-
corticoid receptors and are dependent on protein synthesis,
the precise intracellular signalling mechanism has not been
elucidated. We are currently probing whether the differ-
ential effects of glucocorticoids are mediated by transacti-
vation of the glucocorticoid response element (GRE),
transrepression of other transcription factors [e.g. NF-kB,
activator protein (AP-1)] and interactions with different
transcription factors [cyclicAMP response element binding
protein (CREB), STATs]. There is already good evidence
that glucocorticoid receptors do indeed interact with other
transcription factors in other cell systems (19,20). Hence, it
is possible that the differential effects of glucocorticoids in
regulating neutrophil and eosinophil apoptosis may be due
to divergent effects on transcriptional regulation of
apoptosis in the two cell types. We therefore believe that
understanding the molecular mechanisms controlling apop-
tosis, especially at the transcriptional level, will help in the
search for therapeutic agents that can selectively drive
granulocyte apoptosis.Acknowledgements
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In general, atopy is defined by specific sensitization to
allergens. However, at present there is scant evidence thatallergy is central to the development of atopic dermatitis.
Despite their atopic constitution, many patients with mild
to moderate atopic dermatitis do not have clinically
relevant food or aeroallergen sensitivities; therefore, con-
troversy has surrounded the contribution of IgE-mediated
hypersensitivity to the pathogenesis of atopic dermatitis
classically belonging to the atopic diseases. Elevated blood
eosinophil counts are common in atopic dermatitis and
immigration and degranulation of activated eosinophils is
observed in lesional skin. Thus, the regulation of eosinophil
survival may represent a major mechanism through which
functional eosinophil are accumulated in inflammatory
sites. It is well known that several cytokines, including GM-
CSF, IL-5 and IL-3, are able to support eosinophil survival
and delay apoptosis. We compared eosinophil survival and
apoptosis in non-atopic volunteers and in patients with
inhalant allergy or acute exacerbation of atopic dermatitis.
In eosinophils from subjects with inhalant allergy, and
particularly with atopic dermatitis, eosinophil survival was
prolonged due to delayed apoptosis when compared to
eosinophil from non-atopic subjects (1). There was no
difference in the occurrence of apoptosis between the
extrinsic and the intrinsic type of atopic dermatitis, pointing
to a secondary role of specific sensitization. IL-34GM-
CSF4IL-5 were able to increase viability of cultured
eosinophil in non-atopics and subjects with inhalant
allergy, but were hardly able to further increase eosinophil
survival in subjects with atopic dermatitis which was
increased per se. Eosinophil supernatants of patients with
atopic dermatitis more than of patients with inhalant
allergy dose-dependently inhibited apoptosis in non-atopic
eosinophil, and it was shown by cytokine specific ELISA
that this effect was possibly due to autocrine production of
GM-CSF, probably IL-5, but not IL-3 or TGF-b1. The
observed effects in atopic dermatitis were, in fact, mediated
by an autocrine production of GM-CSF, since neutralizing
anti-GM-CSF mAbs significantly reduced atopic dermatitis
eosinophil survival. Moreover, analysing the effect of
several other cytokines on eosinophil apoptosis, IL-1b,
IL-8, IL-12, platelet activating factor, TNF-a and eotaxin
did not show any effect. However, IL-4 dose-dependently
inhibited eosinophil survival by inducing apoptosis (2). This
effect was abrogated by pre-incubation with neutralizing
anti-IL-4 antibodies and was most evident in atopic
dermatitis eosinophils. However, in co-incubation experi-
ments IL-4 did not overcome the survival-prolonging effect
of IL-3, IL-5 and GM-CSF. Moreover, IL-3, IL-5, GM-
CSF and IL-4 did not modulate eosinophil surface
expression of APO-1/Fas antigen (CD95), and Fas antigen
expression was similar between the groups studied. How-
ever, in inhalant allergy, and particularly in atopic
dermatitis, eosinophils demonstrated a certain resistance
to anti-Fas mAb induced apoptosis when compared to non-
atopic eosinophils (3). The pathomechanism of this
resistance to anti-Fas mAb as well as the mechanisms for
induction of eosinophil apoptosis in general remain
uncertain. The role of oxidative stress has not been
investigated. Thus, we next analysed the role of reactive
oxygen species and selective antioxidants in eosinophil
apoptosis. Eosinophils were cultured with the heavy metal
